Digestive System Diseases, Fatty Liver, Liver Diseases, Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
Conditions
Keywords
diosmectite, nutraceuticals, non-alcoholic fatty liver disease, probiotics, Lactobacillus, Bifidobacterium, Propionibacterium
Brief summary
Smectite is a natural silicate clay belonging to the dioctahedral smectite class and has the ability directly to absorb bacterial toxins, bacteria, viruses and bile salts. Diosmectite also has a protective effect against intestinal inflammation hence suppressing production of cytokines such as IL-8 and TNFα. Investigators suggested that all these pharmacological properties may be beneficial for the treatment of NAFLD. Based on preclinical data, in rats with MSG induced obesity supplementation of alive probiotics with smectite gel (Symbiter-Forte) due to his absorbent activity lead to significant reduction of chronic systemic inflammatory markers, lower total NAS (NAFLD activity score) score, with more pronounced reduction of lobular inflammation as compared to administration of probiotic alone. In respect to preclinical data, in this double-blind single center randomized clinical trial (RCT) the efficacy of alive probiotics supplementation with smectite gel (Symbiter-Forte) vs. placebo in type-2 diabetes patient with NAFLD detected on ultrasonography will be studied
Detailed description
In this single-center double-blind, placebo controlled, parallel group study, 50 T2D patients from the Kyiv City Clinical Endocrinology Center - Ukraine, were selected. They were randomly assigned to receive Symbiter Forte or placebo for 8 weeks, administered as a sachet formulation in double-blind treatment. Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention. The Symbiter Forte was supplied by Scientific and Production Company O.D. Prolisok. It contains combination of smectite gel (250 mg), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patients received 1 sachet (10 grams) of probiotic-smectite and placebo per day. All sachets were identical with similar organoleptic characteristics (e.g., taste and appearance). The pre-randomization period was designed to minimize the effects of dietary changes on metabolic markers. For this purpose, 2 weeks before the study started, after the informed consent was signed, patients were instructed in one-on-one sessions with a dietitian to follow a therapeutic lifestyle-change diet as classified by the NCEP. In addition, participants were instructed to continue with stable anti-hyperglycemic treatment and received standardized mild physical training for 1 hour per day. Patients who underwent the study were instructed to take the trial medication as prescribed. Throughout the study, weekly phone follow-up visits were provided for assessment of compliance, adherence to the protocol, as well as the recording of adverse events. The effectiveness of therapy was compared and evaluated separately in the two groups.
Interventions
DIETARY_SUPPLEMENTSymbiter Forte
Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)
DIETARY_SUPPLEMENTPlacebo
Sponsors
Nazarii Kobyliak
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention.
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* adult participants (ages 18-75, BMI ≥25 kg/m2) diagnosed with NAFLD according to the recommendations of the American Gastroenterology Association (AGA) and American Association for the Study of Liver Disease (AASLD); * the diagnosis of fatty liver was based on the results of abdominal ultrasonography. Of 4 known criteria (hepato-renal echo contrast, liver brightness, deep attenuation, and vascular blurring), the participants were required to have hepato-renal contrast and liver brightness to be given a diagnosis of NAFLD. * type 2 diabetes treated with diet and exercise alone or metformin, SUs and insulin at stable dose at least 4 weeks prior to the commencement of the study; * AST and ALT ≤3x upper limit of normal.
Exclusion criteria
* alcohol abuse (\>20 g/day (2 standard drinks) in women or \> 30 g/d (3 drinks) in men over a two-year period); * chronic viral hepatitis (associated with HBV, HCV, HDV infection); * drug-induced liver disease, Wilson's disease, hereditary deficiency of antitrypsin-1 and idiopathic hemochromatosis; * history of decompensated liver disease including ascites, encephalopathy or variceal bleeding; * regular use of a probiotic or prebiotic supplement within 3 months prior to enrollment; * antibiotic use within 3 months prior to enrollment; * uncontrolled cardiovascular or respiratory disease, active malignancy, or chronic infections; * use of agents such as vitamin E, omega-3 fatty acids or medications with evidence for effects on NAFLD (pioglitazone, GLP-1 analogues, dipeptidyl peptidase IV inhibitors, ursodeoxycholic acid); * presence of active infection, pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| fatty liver index (FLI) | 8 weeks compared to baseline | FLI = \[e 0.953\*loge (triglycerides) + 0.139\*BMI + 0.718\*loge (ggt) + 0.053\*waist circumference - 15.745) / (1 + e 0.953\*loge (triglycerides) + 0.139\*BMI + 0.718\*loge (ggt) + 0.053\*waist circumference - 15.745)\] × 100 |
| liver stiffness (LS) | 8 weeks compared to baseline | liver stiffness (LS) was measured by Shear Wave Elastography (SWE) and expressed in kPa |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ALT | 8 weeks compared to baseline | ALT in IU/L |
| AST | 8 weeks compared to baseline | AST in IU/L |
| γ-GT | 8 weeks compared to baseline | γ-GT in IU/L |
| VLDL-Cholesterol (VLDL-C) | 8 weeks compared to baseline | VLDL-C in mmol/l |
| Tryglicerides (TG) | 8 weeks compared to baseline | TG in mmol/l |
| LDL-Cholesterol (LDL-C) | 8 weeks compared to baseline | LDL-C in mmol/l |
| cytokines levels | 8 weeks compared to baseline | TNF-α, IL-1β, IL-6, IL-8, INF-γ in pg/ml |
| Total Cholesterol (TC) | 8 weeks compared to baseline | TC in mmol/l |
| HDL-Cholesterol (HDL-C) | 8 weeks compared to baseline | HDL-C in mmol/l |
Outcome results
None listed